Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 255

Sort by

Sort Order Select

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, MD PhD, Roberto E. Cacchione, MD, Wojciech Jurczak, MD PhD, Cheolwon Suh, Lorenz Truemper, MD, Christian W Scholz

Blood (2019) 134 (Supplement_1): 5263.

https://doi.org/10.1182/blood-2019-124192

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Mengyang Di, MD PhD, Thomas A Ollila, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3477.

https://doi.org/10.1182/blood-2019-121959

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Long Term Follow-up in Mantle Cell Lymphoma Patients Treated with R-GemOx Followed By Consolidation and Rituximab Maintenance

Marta Garcia Recio, Leyre Bento, MD, Sandra Pérez-León, Sara Aida Jiménez-Julià, Jordi Gines, Jordi Martínez-Serra, PhD, Antonia Sampol, MD PhD, Antonio Gutiérrez, MD PhD

Blood (2018) 132 (Supplement 1): 5337.

https://doi.org/10.1182/blood-2018-99-119713

Published: 2018

Journal Articles

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Blood (2018) 132 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2018-99-117767

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Sirin Khajavian, MD, Matthew Lewis Chase, Justin Darrah, MD, David G. Maloney, MD PhD, Vincent T. Ho, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Stephen J Forman, Auayporn P. Nademanee, MDBS, Yi-Bin Chen, MD, Philippe Armand, MD PhD, Mazyar Shadman, MD MPH

Blood (2018) 132 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2018-99-114155

Published: 2018

Journal Articles

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Camille E. Puronen, MD, Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Brenda M. Sandmaier, MD, Mary E. Flowers, MD, Damian J. Green, MD, David G. Maloney, MD PhD, Rainer F. Storb, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 4559.

https://doi.org/10.1182/blood.V130.Suppl_1.4559.4559

Published: 2017

Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Vaibhav Agrawal, MD MBA, Smelser T. Diane, PhD, Jose I. Castillo, MD, Kelly Raup, RN, Girton D. Treanna, RN, Scotty R. Collins, MD, James O. Brady, MD, Sharif S. Khan, MD

Blood (2017) 130 (Supplement 1): 4066.

https://doi.org/10.1182/blood.V130.Suppl_1.4066.4066

Published: 2017

Journal Articles

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Deborah M. Stephens, DO, Hongli Li, MS, Daniel Persky, MD, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Carla Casulo, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 4122.

https://doi.org/10.1182/blood.V130.Suppl_1.4122.4122

Published: 2017

Journal Articles

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Daniel Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 1553.

https://doi.org/10.1182/blood.V130.Suppl_1.1553.1553

Published: 2017

Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Cristiana A Costa, DO, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd A MacKenzie, PhD, Anne W Beaven, MD, Frederick Lansigan, MD

Blood (2016) 128 (22): 1793.

https://doi.org/10.1182/blood.V128.22.1793.1793

Published: 2016

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD

Blood (2016) 128 (22): 1806.

https://doi.org/10.1182/blood.V128.22.1806.1806

Published: 2016

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy

Sumimasa Nagai, MD, PhD, Keiya Ozawa, MD PhD

Blood (2016) 128 (22): 2387.

https://doi.org/10.1182/blood.V128.22.2387.2387

Published: 2016

Journal Articles

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Marcio Andrade-Campos, MD PhD, Natalia Espinosa-Lara, MD, Paola Lievano, MD PhD, Luis Lopez-Gomez, MD PhD, Teresa Baringo, MD, Pilar Giraldo, MD PhD

Blood (2016) 128 (22): 5323.

https://doi.org/10.1182/blood.V128.22.5323.5323

Published: 2016

NARROW

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Long Term Follow-up in Mantle Cell Lymphoma Patients Treated with R-GemOx Followed By Consolidation and Rituximab Maintenance

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma

Long-Term Follow up of 90 y-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B-Cell Lymphoma

Efficacy of 90Y-Ibritumomab Tiuxetan in the Older Population with Non-Hodgkin Lymphoma Pre-Treated with Rituximab-Based Regimens: A Single-Institution Experience

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Analysis of Drugs for Hematological Malignancy That Were Granted Accelerated Approval and Feasibility of Randomized Phase 3 Clinical Trials for Relapsed and Refractory Hematological Malignancy

90Y-Ibritumomab-Tiuxetan Consolidation in First-Line Complete Response Follicular Lymphoma Patients. Single Center Outcomes Analysis after Five Years Median Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only